Innovations in Insulin Therapy Explored: How Can DCES Make the Most of Biosimilar Insulins to Improve Outcomes?

Developed through a partnership between Medscape and the Association of Diabetes Care & Education Specialists

A recent change to regulatory requirements for biosimilar products may drastically increase the number of biosimilar insulins available in the U.S. This increase in market competitiveness is hoped to reduce insulin prices and ultimately increase the number of individuals with diabetes who can afford their insulin. Medscape recently sat with Susan Cornell, PharmD, CDCES, a professor and author) to discuss biosimilar insulins and what diabetes care and education specialists need to know.
.25 CE for nurses and pharmacists

Supported by an independent educational grant from Sandoz